$IKT Interesting that 1st Biotherapeutics c-Abl inhibitor FB-101 is now moving forward after Inhibikase closed out and unblinded their phase 1b study. FB-101 SAD study began in 2019 and must have completed years ago? has it been on the shelf for 2 years? What does this mean? Did they get funding recently? Did they get a heads up of Inhibikase 1b efficacy results? 1st bio therapeutics also has a relationship with JHU, Neuraly, and The Dawsons. m.biospectator.com/view/new...
퍼스트바이오, 'c-Abl 저해제' 美1상 "연내 파트2 시작"via: 바이오스펙테이터